Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Feb;46(1):219-222.
doi: 10.1111/jcpt.13257. Epub 2020 Sep 28.

Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance

Maiko Abumiya  1 , Naoto Takahashi  2 , Tomoko Yoshioka  2 , Yoshihiro Kameoka  2   3 , Masatomo Miura  1
Affiliations
Case Reports

Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance

Maiko Abumiya et al. J Clin Pharm Ther. 2021 Feb.

Abstract

What is known and objective: Some patients with chronic myeloid leukaemia (CML) cannot continue tyrosine kinase inhibitor (TKI) treatment due to intolerance associated with higher plasma concentration.

Case summary: A 76-year-old woman with chronic-phase CML who showed resistance/intolerance to pre-TKIs has been treated with ponatinib. A high ponatinib bioavailability was noted; therefore, we administered ponatinib 15 mg/3 d to avoid adverse events due to high exposure. Eventually, the patient achieved a major molecular response.

What is new and conclusion: Monitoring of the ponatinib plasma concentration led to safe and effective CML management in a patient with higher drug bioavailability.

Keywords: bioavailability; chronic myeloid leukaemia; intolerance; plasma concentrations; ponatinib.

PubMed Disclaimer

References

REFERENCES

    1. NCCN. NCCN clinical practice guidelines in oncology. Chronic Myeloid Leukemia. 2020;version 3.
    1. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872-884.
    1. Abumiya M, Miura M, Takahashi N. Therapeutic drug monitoring of ponatinib using a simple high-performance liquid chromatography method in Japanese patients. Leuk Res. 2017;64:42-45.
    1. Macphee IA, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation. 2002;74:1486-1489.
    1. Tojo A, Kyo T, Yamamoto K, et al. Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study. Int J Hematol. 2017;106:385-397.

Publication types

MeSH terms

Grants and funding